Activation and binding of peroxisome proliferator-activated receptor γ by synthetic cannabinoid ajulemic acid

Molecular Pharmacology

Volumn 63, Issue 5, 2003, Pages 983-992

  Liu, Jilin ^a   Li, Hui ^a   Burstein, Sumner H ^a   Zurier, Robert B ^a   Chen, J Don ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AJULEMIC ACID; CANNABINOID; CANNABIS; CELL NUCLEUS RECEPTOR; HYBRID PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ADIPOCYTE; ANALGESIC ACTIVITY; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CELL STRAIN 3T3; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG STRUCTURE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

ADIPOCYTES; BINDING SITES; CELL DIFFERENTIATION; CELLS, CULTURED; HUMANS; INTERLEUKIN-8; PROMOTER REGIONS (GENETICS); RECEPTORS, CYTOPLASMIC AND NUCLEAR; TETRAHYDROCANNABINOL; TRANSCRIPTION FACTORS;

EID: 0038745585     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.5.983     Document Type: Article

References (50)

1. Allan GF, Leng X, Tsai SY, Weigel NL, Edwards DP, Tsai MJ, and O'Malley BW (1992) Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem 267:19513-19520.
2. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, and Evans RM (1999) PPAR gamma is required for placental, cardiac and adipose tissue development. Mol Cell 4:585-595.
3. Berger J and Moller DE (2002) The mechanisms of action of PPARs. Annu Rev Med 53:409-435.
4. Burstein SH (2000) Ajulemic acid (CT3): a potent analog of the acid metabolites of THC. Curr Pharm Des 6:1339-1345.
5. Burstein SH, Audette CA, Breuer A, Devane WA, Colodner S, Doyle SA, and Mechoulam R (1992) Synthetic nonpsychotropic cannabinoids with potent antiinflammatory, analgesic and leukocyte antiadhesion activities. J Med Chem 35:3135-3141.
6. Burstein SH, Friderichs E, Kogel B, Schneider J, and Selve N (1998) Analgesic effects of 1′,1′ dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice. Life Sci 63:161-168.
7. Chawla A and Lazar MA (1994) Peroxisome proliferator and retinoid signaling pathways co-regulate preadipocyte phenotype and survival. Proc Natl Acad Sci USA 91:1786-1790.
8. Clark RB, Bishop-Bailey D, Estrada-Hernandez T, Hla T, Puddington L, and Padula SJ (2000) The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol 164:1364-1371.
9. Cobb JE, Blanchard SG, Boswell EG, Brown KK, Charifson PS, Cooper JP, Collins JL, Dezube M, Henke BR, Hull-Ryde EA, et al. (1998) N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 3. Structure-activity relationship and optimization of the N-aryl substituent. J Med Chem 41:5055-5069.
10. Dajani EZ, Larsen KR, Taylor J, Dajani NE, Shahwan TG, Neeleman SD, Taylor MS, Dayton MT, and Mir GN (1999) 1′,1′-Dimethylheptyl-Δ-8-tetrahydrocannabinol-11-oic acid: a novel, orally effective cannabinoid with analgesic and antiinflammatory properties. J Pharmacol Exp Ther 291:31-38.
11. Dubuquoy L, Bourdon C, Peuchmaur M, Leibowitz MD, Nutten S, Colombel JF, Auwerx J, and Desreumaux P (2000) Peroxisome proliferator-activated receptor (PPAR) gamma: a new target for the treatment of inflammatory bowel disease. Gastroenterol Clin Biol 24:719-724.
12. Faubert BL and Kaminski NE (2000) AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J Leukoc Biol 67:259-266.
13. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 83:803-812.
14. Houseknecht KL, Cole BM, and Steele PJ (2002) Peroxisome proliferator-activated receptor gamma (PPARgamma) and its ligands: a review. Domest Anim Endocrinol 22:1-23.
15. Hu E, Tontonoz P, and Spiegelman BM (1995) Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha. Proc Natl Acad Sci USA 92:9856-9860.
16. 9-tetrahydrocannabinol is mediated through the inhibition of nuclear factor-κB/Rel activation. Mol Pharmacol 50:334-41.
17. Ji JD, Cheon H, Jun JB, Choi SJ, Kim YR, Lee YH, Kim TH, Chae IJ, Song GG, Yoo DH, et al. (2001) Effects of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) on the expression of inflammatory cytokines and apoptosis induction in rheumatoid synovial fibroblasts and monocytes. J Autoimmun 17:215-221.
18. Jiang C, Ting AT, and Seed B (1998) PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature (Lond) 391:82-86.
19. 2 induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Investig 106:189-197.
20. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, Umesono K, and Evans RM (1994) Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 91:7355-7359.
21. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, and Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation. Cell 83:813-819.
22. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS, Devchand P, Wahli W, Willson TM, Lenhard JM, et al. (1997) Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferatoractivated receptors alpha and gamma. Proc Natl Acad Sci USA 94:4318-4323.
23. Leblanc BP and Stunnenberg HG (1995) 9-cis retinoic acid signaling: changing partners causes some excitement. Genes Dev 9:1811-1816.
24. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, and Kliewer SA (1997) Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem 272:3406-3410.
25. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, and Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPAR γ). J Biol Chem 270:12953-12956.
26. Leng X, Tsai SY, O'Malley BW, and Tsai MJ (1993) Ligand-dependent conformational changes in thyroid hormone and retinoic acid receptors are potentially enhanced by heterodimerization with retinoic X receptor. J Steroid Biochem Mol Biol 46:643-661.
27. Leo C and Chen JD (2000) The SRC family of nuclear receptor coactivators. Gene 245:1-11.
28. Li H, Gomes PJ, and Chen JD (1997) RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. Proc Natl Acad Sci USA 94:8479-8484.
29. Mukherjee R, Jow L, Croston GE, and Paterniti JR Jr (1997) Identification, characterization and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 272:8071-8076.
30. Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE, and Paterniti JR Jr (2000) A selective peroxisome proliferatoractivated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes. Mol Endocrinol 14:1425-1433.
31. Nagy L, Tontonoz P, Alvarez JG, Chen H, and Evans RM (1998) Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93:229-240.
32. Naito Y, Takagi T, Matsuyama K, Yoshida N, and Yoshikawa T (2001) Pioglitazone, a specific PPAR-gamma ligand, inhibits aspirin-induced gastric mucosal injury in rats. Aliment Pharmacol Ther 15:865-873.
33. Patel L, Pass I, Coxon P, Downes CP, Smith SA, and Macphee CH (2001) Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 11:764-768.
34. Pertwee RG (1997) Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 74:129-180.
35. Ricote M, Li AC, Willson TM, Kelly CJ, and Glass CK (1998) The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature (Lond) 391:79-82.
36. Rosen ED, Hsu CH, Wang X, Sakai S, Freeman MW, Gonzalez FJ, and Spiegelman BM (2002) C/EBPalpha induces adipogenesis through PPARgamma: a unified pathway. Genes Dev 16:22-26.
37. Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 4:1046-1052.
38. Simonin MA, Bordji K, Boyault S, Bianchi A, Gouze E, Becuwe P, Dauca M, Netter P, and Terlain B (2002) PPAR-gamma ligands modulate effects of LPS in stimulated rat synovial fibroblasts. Am J Physiol 282:C125-C133.
39. Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, Sengchanthalangsy LL, Ghosh G, and Glass CK (2000) 15-deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. Proc Natl Acad Sci USA 97:4844-4849.
40. Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, and Sporn MB (1999) A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res 59:5671-5673.
41. Tontonoz P, Hu E, and Spiegelman BM (1994) Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 79:1147-1156.
42. 12,14-prostaglandin J2. Biochem Biophys Res Commun 283:750-755.
43. Umesono K, Murakami KK, Thompson CC, and Evans RM (1991) Direct repeats as selective response elements for the thyroid hormone induced gene expression through a common responsive element. Cell 65:1255-1266.
44. Uppenberg J, Svensson C, Jaki M, Bertilsson G, Jendeberg L, and Berkenstam A (1998) Crystal structure of the ligand binding domain of the human nuclear receptor PPARgamma. J Biol Chem 273:31108-31112.
45. Willson TM, Cobb JE, Cowan DJ, Wiethe RW, Correa ID, Prakash SR, Beck KD, Moore LB, Kliewer SA, and Lehmann JM (1996) The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones. J Med Chem 39:665-668.
46. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, et al. (2001) Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 98:13919-13924.
47. Yang W, Rachez C, and Freedman LP (2000) Discrete roles for peroxisome proliferator-activated receptor gamma and retinoid X receptor in recruiting nuclear receptor coactivators. Mol Cell Biol 20:8008-8017.
48. Zheng ZM and Specter S (1996) Delta-9-tetrahydrocannabinol: an inhibitor of STAT1 alpha protein tyrosine phosphorylation. Biochem Pharmacol 51:967-73.
49. Zhu Y, Qi C, Jain S, Rao MS, and Reddy JK (1997) Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem 272:25500-25506.
50. Zurier RB, Rossetti RG, Lane JH, Goldberg JM, Hunter SA, and Burstein SH (1998) Dimethylheptyl-THC-11 oic acid: a nonpsychoactive anti-inflammatory agent with a cannabinoid template structure. Arthritis Rheum 41:163-170.